Non-comparative phase II trial in 72 patients with grade 1-2 neuroendocrine tumours: 12-month PFS in pancreatic NETs was 83.3% with PRRT/CAPTEM vs 88.9% with CAPTEM; 15-month PFS in small bowel NETs was 90.4% vs 92.3% with PRRT alone.
RCTn = 72 patients
Chan et al. [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial